FilingIndex
8-KThe WireRoutine

Reg FD Disclosure

Filed Jun 23, 2021 · 5y ago · Accession 0001493152-21-015042

Plain English

Material event — a significant development the company must disclose promptly.

Read the source below for the full document.

Securities and Exchange Commission, the information in this Item 7.01 disclosure, including Exhibit 99.1 and information set forth therein, is deemed to have been furnished and shall not be deemed to be “filed” under the Securities Exchange Act of 1934, as amended. Item 9.01. Financial Statements and Exhibits. (d) Exhibits. Exhibit Number Description 99.1 2021 Annual Meeting of Stockholders presentation slides SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: June 23, 2021 PROVECTUS BIOPHARMACEUTICALS, INC. By: /s/ Heather Raines Heather Raines Chief Financial Officer (Principal Financial Officer)
Filing details
Ticker
PVCT
CIK
315545
Form type
8-K
Filing date
Jun 23, 2021
Report date
Jun 23, 2021
Document
form8-k.htm
Size
3.7 MB